Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protagonist Therapeutics (PTGX) Research & Development (2017 - 2025)

Protagonist Therapeutics (PTGX) has disclosed Research & Development for 9 consecutive years, with $46.4 million as the latest value for Q4 2025.

  • Quarterly Research & Development rose 32.82% to $46.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $159.3 million through Dec 2025, up 15.32% year-over-year, with the annual reading at $159.3 million for FY2025, 15.32% up from the prior year.
  • Research & Development hit $46.4 million in Q4 2025 for Protagonist Therapeutics, up from $40.0 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $46.4 million in Q4 2025 to a low of $24.2 million in Q1 2021.
  • Historically, Research & Development has averaged $33.5 million across 5 years, with a median of $34.2 million in 2022.
  • Biggest five-year swings in Research & Development: soared 131.05% in 2021 and later plummeted 31.26% in 2022.
  • Year by year, Research & Development stood at $38.4 million in 2021, then dropped by 22.12% to $29.9 million in 2022, then fell by 3.3% to $28.9 million in 2023, then increased by 20.78% to $34.9 million in 2024, then soared by 32.82% to $46.4 million in 2025.
  • Business Quant data shows Research & Development for PTGX at $46.4 million in Q4 2025, $40.0 million in Q3 2025, and $37.0 million in Q2 2025.